WARNING
THIORIDAZINE HCl HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING THIORIDAZINE, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, THIORIDAZINE SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS AND USAGE).
|
THIORIDAZINE SUMMARY
THIORIDAZINE HCl
TABLETS USP
Thioridazine hydrochloride is 2-methylmercapto-10-[2-(N-methyl-2-piperidyl) ethyl] phenothiazine.
Thioridazine is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with thioridazine treatment, thioridazine should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine, it is strongly recommended that a patient be given at least 2 trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).
However, the prescriber should be aware that thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
|
THIORIDAZINE NEWS HIGHLIGHTS Media Articles Related to Thioridazine
New Study Shows Potential Of Rational Drug Design In Schizophrenia
Source: Health News from Medical News Today [2008.12.01]
Schering-Plough Unveils Top-Line Study Results For SAPHRIS(TM) (asenapine) Demonstrating Efficacy In Long-Term Schizophrenia Relapse Prevention
Source: Schizophrenia News From Medical News Today [2008.11.25]
Memory Pharmaceuticals Achieves Enrollment Goal For Phase 2 Study Of MEM 3454 In Cognitive Impairment Associated With Schizophrenia
Source: Schizophrenia News From Medical News Today [2008.11.20]
Compound Tied to Cognitive Deficits in Schizophrenia
Source: MedicineNet Schizophrenia Specialty [2008.11.20]
Schizophrenia: Brain Compound 'Throws Gasoline Onto The Fire'
Source: Schizophrenia News From Medical News Today [2008.11.19]
Published Studies Related to Thioridazine
Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers. [2004.11]
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. [2002.04]
Psychomotor effects of zaleplon and thioridazine coadministration. [2000.06]
Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. [1999.08.09]
Clinical Trials Related to Thioridazine
Study With IT-Aided Preventive Program in Schizophrenia [Not yet recruiting]
Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment [Recruiting]
|
